Wordt geladen...
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase 1 testing in relapsed/refractory hairy cell leukemia (HCL; n = 28). The importance of minimal residual disease (MRD) after CR in HCL is unknown. A 21-patient extension cohort received 50 µg/kg every o...
Bewaard in:
| Gepubliceerd in: | Blood |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5969375/ https://ncbi.nlm.nih.gov/pubmed/29487070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-803072 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|